HRP20230145T1 - Fuzijski polipeptid protiv raka - Google Patents

Fuzijski polipeptid protiv raka Download PDF

Info

Publication number
HRP20230145T1
HRP20230145T1 HRP20230145TT HRP20230145T HRP20230145T1 HR P20230145 T1 HRP20230145 T1 HR P20230145T1 HR P20230145T T HRP20230145T T HR P20230145TT HR P20230145 T HRP20230145 T HR P20230145T HR P20230145 T1 HRP20230145 T1 HR P20230145T1
Authority
HR
Croatia
Prior art keywords
fusion protein
seq
amino acid
group
acid sequence
Prior art date
Application number
HRP20230145TT
Other languages
English (en)
Inventor
Marlon HINNER
Rachida Siham Bel Aiba
Christine Rothe
Shane Olwill
Corinna SCHLOSSER
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of HRP20230145T1 publication Critical patent/HRP20230145T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (16)

1. Fuzijski protein naznačen time što je fuzijski protein sposoban vezati i CD137 i glipikan-3 (GPC3), i što fuzijski protein sadrži najmanje dvije podjedinice bilo kojim redoslijedom, pri čemu prva podjedinica sadrži lipokalinski mutein specifičan za CD137 koji ima najmanje 85% identičnosti sekvence sa sekvencom odabranom iz skupine koja se sastoji od SEQ ID NO: 18-33 i druga podjedinica sadrži imunoglobulin pune duljine, njegovu domenu koja veže antigen, ili lipokalinski mutein specifičan za GPC3.
2. Fuzijski protein prema zahtjevu 1, naznačen time što druga podjedinica sadrži lipokalinski mutein koji ima specifičnost vezanja za GPC3.
3. Fuzijski protein prema zahtjevu 2, naznačen time što fuzijski protein nadalje sadrži treću podjedinicu koja je (i) fragment imunoglobulina-Fc, (ii) specifično za CD137, ili (iii) lipokalinski mutein koji ima specifičnost vezanja za CD137.
4. Fuzijski protein prema zahtjevu 2 ili 3, naznačen time što lipokalinski mutein koji ima specifičnost vezanja za GPC3 sadrži aminokiselinsku sekvencu koja ima najmanje 85% identičnost sekvence prema sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO: 4-17, ili ima najmanje 90% identičnost sekvence prema sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO: 4-17, ili ima najmanje 95% identičnost sekvence prema sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO: 4-17, ili je odabrana iz skupine koja se sastoji od SEQ ID NO: 4-17.
5. Fuzijski polipeptid prema bilo kojem od zahtjeva 1-4, naznačen time što lipokalinski mutein koji ima specifičnost vezanja za CD137 sadrži sljedeći skup mutiranih aminokiselinskih ostataka u usporedbi s linearnom polipeptidnom sekvencom zrelog hNGAL (SEQ ID NO: 2): Gln 28 → His; Leu 36 → Gln; Ala 40 → Ile; Ile 41 → Arg; Gln 49 → Ile; Tyr 52 → Met; Asn 65 → Asp; Ser 68 → Met; Leu 70 → Lys; Arg 72 → Asp; Lys 73 → Asp; Asp 77 → Met; Trp 79 → Asp; Arg 81 → Trp; Cys 87 → Ser; Asn 96 → Lys; Tyr 100 → Phe; Leu 103 → His; Tyr 106 → Ser; Lys 125 → Phe; Ser 127 → Phe; Tyr 132 → Glu; i Lys 134 → Tyr.
6. Fuzijski protein prema bilo kojem od zahtjeva 1-5, naznačen time što (i) lipokalinski mutein koji ima specifičnost vezanja za CD137 ima najmanje 90% identičnosti sekvence sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID NO: 18-33; (ii) lipokalinski mutein koji ima specifičnost vezanja za CD137 ima najmanje 95% identičnosti sekvence sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID NO: 18-33; ili (iii) lipokalinski mutein koji ima specifičnost vezanja za CD137 sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 18-33.
7. Fuzijski protein prema bilo kojem od zahtjeva 1-6, naznačen time što fuzijski polipeptid sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO: 48 ili aminokiselinsku sekvencu prikazanu u SEQ ID NO: 49.
8. Fuzijski protein prema bilo kojem od zahtjeva 1-7, naznačen time što je imunoglobulin monoklonsko antitijelo.
9. Fuzijski protein prema zahtjevu 8, naznačen time što (a) monoklonsko antitijelo ima okosnicu IgG4, pri čemu izborno okosnica IgG4 ima bilo koju od sljedećih mutacija odabranih iz skupine koju čine S228P, N297A, F234A, i L235A; ili (b) monoklonsko antitijelo ima okosnicu IgG2, pri čemu izborno okosnica IgG2 ima bilo koju od sljedećih mutacija odabranih iz skupine koju čine N297A, F234A, i L235A.
10. Fuzijski protein prema bilo kojem od zahtjeva 1-9, naznačen time što fuzijski protein sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO: 44, aminokiselinsku sekvencu prikazanu u SEQ ID NO: 45, aminokiselinsku sekvencu prikazanu u SEQ ID NO: : 46, ili aminokiselinsku sekvencu prikazanu u SEQ ID NO: 47.
11. Molekula nukleinske kiseline koja sadrži nukleotidnu sekvencu koja kodira fuzijski protein prema bilo kojem od zahtjeva 1-10.
12. Stanica domaćina koja sadrži molekulu nukleinske kiseline prema zahtjevu 11.
13. In vitro metoda proizvodnje fuzijskog proteina prema bilo kojem od zahtjeva 1-10, naznačena time što se fuzijski protein proizvodi počevši od nukleinske kiseline koja kodira fuzijski protein pomoću metoda genetskog inženjeringa, pri čemu se izborno fuzijski protein proizvodi u bakterijski ili eukariotski organizam domaćin i izoliran je iz tog organizma domaćina ili njegove kulture.
14. Fuzijski protein prema bilo kojem od zahtjeva 1-10, naznačen time što je za uporabu u liječenju raka.
15. Fuzijski protein za uporabu prema zahtjevu 14, naznačen time što sadrži (i) istovremeno aktiviranje nizvodnih signalnih puteva CD137 i uključivanje GPC3-pozitivnih tumorskih stanica, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein; (ii) istovremenu kostimulaciju T stanica i uključivanje GPC3-pozitivnih tumorskih stanica, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein; (iii) istovremeno induciranje proliferacije T limfocita i uključivanje GPC3-pozitivnih tumorskih stanica, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein; ili (iv) usmjeravanje CD137 grupiranja i aktivacije T stanica na GPC3-pozitivne tumorske stanice, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein.
16. Farmaceutski pripravak koji sadrži fuzijski protein prema bilo kojem od zahtjeva 1-10.
HRP20230145TT 2015-05-18 2016-05-18 Fuzijski polipeptid protiv raka HRP20230145T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15167927 2015-05-18
EP16150508 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide
EP16729794.4A EP3298030B1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Publications (1)

Publication Number Publication Date
HRP20230145T1 true HRP20230145T1 (hr) 2023-04-28

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230145TT HRP20230145T1 (hr) 2015-05-18 2016-05-18 Fuzijski polipeptid protiv raka

Country Status (22)

Country Link
US (2) US10913778B2 (hr)
EP (2) EP3298030B1 (hr)
JP (1) JP6947642B2 (hr)
KR (1) KR20180002855A (hr)
CN (1) CN108112253B (hr)
AU (1) AU2016262845B2 (hr)
BR (1) BR112017020445A2 (hr)
CA (1) CA2980838A1 (hr)
DK (1) DK3298030T3 (hr)
ES (1) ES2938525T3 (hr)
FI (1) FI3298030T3 (hr)
HR (1) HRP20230145T1 (hr)
HU (1) HUE061108T2 (hr)
LT (1) LT3298030T (hr)
MX (1) MX2017014716A (hr)
PL (1) PL3298030T3 (hr)
RS (1) RS64002B1 (hr)
RU (2) RU2021119777A (hr)
SG (1) SG11201707426SA (hr)
SI (1) SI3298030T1 (hr)
WO (1) WO2016184882A1 (hr)
ZA (1) ZA201706061B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
WO2016177762A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US10501510B2 (en) 2015-07-15 2019-12-10 Pieris Pharmaceuticals Gmbh Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN110461873B (zh) * 2017-01-03 2023-05-12 豪夫迈·罗氏有限公司 包含抗4-1bb克隆20h4.9的双特异性抗原结合分子
EP3565840A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CA3050194A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for lag-3
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EP3710477A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Single domain antibodies that bind to cd137
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
KR20200136949A (ko) 2018-03-26 2020-12-08 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물
LT3830120T (lt) * 2018-07-31 2023-07-10 Pieris Pharmaceuticals Gmbh Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu
BR112021016829A2 (pt) 2019-02-26 2021-10-19 Pieris Pharmaceuticals Gmbh Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres
WO2020208049A1 (en) * 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
CA3142513A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
WO2024064713A1 (en) * 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
MX9605717A (es) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2002024866A2 (en) 2000-09-21 2002-03-28 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
ES2354653T3 (es) 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
WO2008015239A2 (en) * 2006-08-01 2008-02-07 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
EP2178921B1 (en) 2007-07-17 2016-01-06 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against glypican-3
WO2009052390A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
CN102770764B (zh) 2009-12-07 2016-04-20 皮里斯股份公司 对给定靶标具有亲和力的人脂质运载蛋白2(Lcn2,hNGAL)的突变蛋白
KR101918024B1 (ko) 2010-08-16 2018-11-14 피어이스 파마슈티컬즈 게엠베하 헵시딘 결합 단백질
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
EP2640740B1 (en) 2010-11-15 2017-03-15 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2928913A1 (en) * 2012-12-10 2015-10-14 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
TWI726842B (zh) * 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
MX2017009767A (es) 2015-01-28 2018-08-15 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
CR20170425A (es) 2015-02-18 2017-11-22 Sanofi Sa Nuevas proteínas específicas para pioverdina y pioquelina
SG11201708334RA (en) 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
WO2016177762A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
KR20180008649A (ko) 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
SI3298030T1 (sl) 2023-05-31
CN108112253B (zh) 2022-09-23
ES2938525T3 (es) 2023-04-12
JP6947642B2 (ja) 2021-10-13
RU2754466C2 (ru) 2021-09-02
LT3298030T (lt) 2023-02-27
CN108112253A (zh) 2018-06-01
FI3298030T3 (fi) 2023-02-22
MX2017014716A (es) 2018-06-28
DK3298030T3 (en) 2023-02-06
HUE061108T2 (hu) 2023-05-28
WO2016184882A1 (en) 2016-11-24
ZA201706061B (en) 2022-05-25
AU2016262845B2 (en) 2020-07-23
AU2016262845A1 (en) 2018-01-04
JP2018519803A (ja) 2018-07-26
US20180148485A1 (en) 2018-05-31
RS64002B1 (sr) 2023-03-31
RU2017135539A3 (hr) 2019-11-29
RU2017135539A (ru) 2019-06-18
EP3298030A1 (en) 2018-03-28
SG11201707426SA (en) 2017-10-30
BR112017020445A2 (pt) 2018-07-03
KR20180002855A (ko) 2018-01-08
RU2021119777A (ru) 2021-08-16
US10913778B2 (en) 2021-02-09
US20210403516A1 (en) 2021-12-30
EP3298030B1 (en) 2023-01-18
EP4219535A1 (en) 2023-08-02
US11919931B2 (en) 2024-03-05
PL3298030T3 (pl) 2023-05-08
CA2980838A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
HRP20230145T1 (hr) Fuzijski polipeptid protiv raka
KR102436129B1 (ko) T 세포 수용체 및 이의 용도
HRP20210011T1 (hr) Metoda i pripravci za staničnu imunoterapiju
HRP20201392T1 (hr) Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste
Kazane et al. Self-assembled antibody multimers through peptide nucleic acid conjugation
JP2018519803A5 (hr)
Siegemund et al. An optimized antibody-single-chain TRAIL fusion protein for cancer therapy
HRP20200640T1 (hr) De-imunizirane, okosnice podjedinice shiga toksina a i molekule koje ciljaju stanice koje ih sadrže
HRP20230590T1 (hr) Novi fuzijski protein specifičan za cd137 i pd-l1
US9644020B2 (en) Human Tim-3 fusion protein capable of blocking Tim-3 signaling pathway
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
JP2014523238A (ja) インターフェロンと標的化修飾ユビキチンタンパク質とを含むヒト融合タンパク質
MX2023007282A (es) Moleculas de union al antigeno especificas para la variante ror1.
CN103237808A (zh) 抗癌融合蛋白
JP2022528030A (ja) 多機能性融合タンパク質及びその使用
KR20200120648A (ko) 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법
US20240166754A1 (en) Il12rb1-binding molecules and methods of use
CN115103852A (zh) Prame tcr受体和其用途
AU2023251563A1 (en) Biased IL2 muteins methods and compositions
CA3025124A1 (en) Herpesvirus with modified glycoprotein h for propagation in a cell
NZ724196A (en) Uti fusion proteins
CN108264560B (zh) 一种结合cd3和cd28的双功能分子及其应用
JP2017508446A (ja) 二機能性融合タンパク質及びその製造方法並びに使用
CA3234552A1 (en) Heterodimeric fc cytokines and uses thereof
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)